GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Other Income (Expense)

Ryvu Therapeutics (WAR:RVU) Other Income (Expense) : zł6.89 Mil (TTM As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Other Income (Expense)?

Ryvu Therapeutics's other income expense for the Ryvu Therapeutics's pretax income for the three months ended in Dec. 2024 was zł7.14 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was zł6.89 Mil.

Ryvu Therapeutics Other Income (Expense) Historical Data

The historical data trend for Ryvu Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Other Income (Expense) Chart

Ryvu Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.46 1.78 -9.76 -8.47 5.51

Ryvu Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.47 0.79 0.33 -1.37 7.14

Ryvu Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł6.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics  (WAR:RVU) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Ryvu Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Other Income (Expense)
Comparable Companies
WAR:BCX WAR:SVE WAR:BIO WAR:CTX WAR:MOC WAR:PTG WAR:MAB WAR:URT WAR:NNG WAR:PHR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
9Y4:Germany
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Website
https://www.ryvu.com
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines